David Magier, MD
Internal Medicine · Lake Success, NYNPI 1285634196
Payments from drug & device makers
Across 682 payments — averaging $35.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
- Gilead$2K
- Madrigal Pharmaceuticals$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Amgen$1K
- plus $8K from 29 others
What the payments were for
- Speaking & faculty fees$4,95520%
- Travel & lodging$1160%
- Food & beverage$19,24979%
- Education$1231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $6,001 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 154 | $2,706 |
| Gilead | 68 | $2,457 |
| Madrigal Pharmaceuticals | 32 | $2,010 |
| E.r. Squibb & Sons, L.L.C. | 19 | $1,903 |
| Amgen | 47 | $1,085 |
| Ardelyx, Inc. | 29 | $1,060 |
| Phathom Pharmaceuticals, Inc. | 45 | $848 |
| Pfizer | 34 | $773 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $758 |
| Nestle Healthcare Nutrition Inc. | 14 | $718 |
| Bristol Myers Squibb | 36 | $652 |
| AstraZeneca | 22 | $488 |
| Teva Pharmaceuticals USA, Inc. | 3 | $375 |
| Ipsen Biopharmaceuticals, Inc | 5 | $319 |
| Novo Nordisk | 12 | $316 |
| Redhill Biopharma Inc. | 20 | $306 |
| Ferring Pharmaceuticals Inc. | 12 | $207 |
| Kowa Pharmaceuticals America, Inc. | 11 | $178 |
| Regeneron Healthcare Solutions, Inc. | 8 | $168 |
| Johnson & Johnson | 2 | $156 |
| Astellas Pharma US Inc | 5 | $152 |
| Sanofi | 1 | $142 |
| Intercept Pharmaceuticals, Inc. | 1 | $125 |
| Evoke Pharma, Inc. | 1 | $118 |
| Merck | 7 | $109 |
| Amarin Pharma, Inc. | 4 | $81 |
| Sanofi-aventis U.S. LLC | 2 | $78 |
| Boehringer Ingelheim | 3 | $52 |
| Braintree Laboratories, Inc. | 2 | $38 |
| Lilly USA, LLC | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Boston Scientific | 1 | $13 |
| Seqirus USA Inc | 1 | $11 |
| QOL Medical, LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,442 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GattexTeduglutide | 12 | $544,142 |
| MounjaroTirzepatide | 133 | $189,716 |
| Clemastine Fumarate | 13 | $115,192 |
| Repatha SureclickEvolocumab | 129 | $95,581 |
| OzempicSemaglutide | 61 | $86,533 |
| EliquisApixaban | 80 | $80,986 |
| LinzessLinaclotide | 88 | $74,421 |
| JanumetSitagliptin Phos/Metformin Hcl | 55 | $69,492 |
| JardianceEmpagliflozin | 48 | $57,095 |
| XifaxanRifaximin | 21 | $52,802 |
| FarxigaDapagliflozin Propanediol | 45 | $50,613 |
| JanuviaSitagliptin Phosphate | 41 | $47,444 |
| XareltoRivaroxaban | 34 | $46,147 |
| Dexlansoprazole DrDexlansoprazole | 144 | $35,680 |
| TrulancePlecanatide | 36 | $24,554 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $758 | $544,14212 claims |
| Lilly USA, LLCMounjaro | $16 | $189,716133 claims |
| MerckJanumet, Januvia | $109 | $116,93696 claims |
| Novo NordiskOzempic | $316 | $86,53361 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu | $2,706 | $81,93690 claims |
| PfizerEliquis | $773 | $80,98680 claims |
| AbbVieLinzess, Synthroid | $6,001 | $80,928187 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Crestor | $488 | $72,77571 claims |
| Boehringer IngelheimJardiance, Tradjenta | $52 | $70,13364 claims |
| Johnson & JohnsonXarelto | $156 | $46,14734 claims |
| Astellas Pharma US IncMyrbetriq | $152 | $24,08628 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $15 | $19,72234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Lake Success
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.